Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How The Prostate Cancer Market Will Look Over Next Decade

Executive Summary

As generic competition to J&J's Zytiga starts to line up ahead of possible launches in October, Datamonitor Healthcare has been weighing up the prostate cancer therapy space and seeing where the future competition will come from for Pfizer and Astellas' market leader Xtandi.


Related Content

Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
Prostate Cancer Approaches, Treatment Evolve In Asia Amid Wider Therapy Shifts
J&J Growth Plans Heavy On Line Extensions, Sticking With Immunology And Oncology
Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer
A First For Prostate Cancer: Janssen's Erleada Approved For Non-Metastatic Patients
Small Study Offers Hope For PARP/PD-L1 Combos In Prostate Cancer
PTAB Clears Path For Earlier Generic Zytiga Launch
J&J Hopes To Reach Market First For Pre-Metastatic Prostate Cancer With Apalutamide
Pfizer Poised To PROSPER From Xtandi In Expanded Indication


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts